Sustained response to interferon-α2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C

Journal of Viral Hepatitis

Volumn 7, Issue 5, 2000, Pages 352-360

  Prati, ^a,b,c,d   Zanella, ^a,b,c,d   Zanuso, ^a,b,c,d   Vianello, ^a,b,c,d   Della Torre, E ^a,b,c,d   Mozzi, ^a,b,c,d   Carriero, ^a,b,c,d   Zahm, ^a,b,c,d   Donato, ^a,b,c,d   Colombo, ^a,b,c,d   Sirchia, ^a,b,c,d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Hepatitis C virus; Liver histology; Normal ALT; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; ARTICLE; BLOOD DONOR; CHRONIC HEPATITIS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER NECROSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BLOOD DONORS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0033822117     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2000.00240.x     Document Type: Article

References (44)

1. Management of hepatitis C
2. Consensus statement
3. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection
4. A role for hepatitis C virus infection in type II cryoglobulinemia
5. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection
6. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection
7. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma
8. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
9. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection
10. Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second generation recombinant immunoblot assay
11. Asymptomatic hepatitis G virus infection in blood donors
12. Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels
13. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy
14. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study
15. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: Results of the National Hepatitis Screening Survey
16. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups
17. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
18. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
19. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
20. HCV-associated liver cancer without cirrhosis
21. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity
22. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: The role of interferon alpha 2b therapy
23. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment
24. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study
25. Interferon-alpha 2b therapy in low-activity hepatitis C: A pilot study
26. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis
27. Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels
28. Therapy of hepatitis C: Patients with normal aminotransferase levels
29. Follow-up of blood donors with hepatitis C vires infection
30. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
31. Classification of chronic hepatitis: Diagnosis, grading and staging
32. Essential and secondary monoclonal gammopathies
33. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
34. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
35. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
36. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
37. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C
38. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels
39. Hepatitis C viremia and liver disease in symptom-free individuals with anti-HCV
40. Factors associated with serum alanine transaminase activity in healthy subjects consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group
41. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison